Supernus Pharmaceuticals (SUPN) Other Non Operating Income (2011 - 2025)

Supernus Pharmaceuticals (SUPN) has 15 years of Other Non Operating Income data on file, last reported at $2.0 million in Q4 2025.

• On a quarterly basis, Other Non Operating Income fell 59.35% year-over-year to $2.0 million in Q4 2025; TTM through Dec 2025 was $13.3 million, a 18.21% decrease from a year earlier, with the FY2025 full-year figure at $13.3 million, down 18.21% from the prior year.
• Other Non Operating Income for Q4 2025 stood at $2.0 million, down from $2.3 million in the prior quarter.
• Over the last five years, Other Non Operating Income for SUPN reached as high as $14.7 million in Q1 2022 and fell as low as -$21.5 million in Q4 2021.
• Historically, Other Non Operating Income has averaged $2.4 million across 5 years, with a median of $2.7 million in 2021.
• Across the five-year window, Other Non Operating Income jumped 285.57% in 2022 and plunged 63.63% in 2023, its largest moves.
• Year by year, Other Non Operating Income stood at -$21.5 million in 2021, then jumped by 111.14% to $2.4 million in 2022, then retreated by 17.25% to $2.0 million in 2023, then surged by 150.6% to $5.0 million in 2024, then sank by 59.35% to $2.0 million in 2025.
• Per Business Quant data, the three most recent Other Non Operating Income figures were $2.0 million in Q4 2025, $2.3 million in Q3 2025, and $4.5 million in Q2 2025.